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Abstract The NR4A transcription factors NR4A1, NR4A2,
and NR4A3 (also known as Nur77, Nurr1, and Nor1,
respectively) share similar DNA-binding properties and have
been implicated in regulation of dopamine neurotransmission
genes. Our current hypothesis is that NR4A gene expression is
regulated by dopamine neuron activity and that induction of
NR4A genes will increase expression of dopamine neuro-
transmission genes. Eticlopride and γ-butyrolactone (GBL)
were used in wild-type (+/+) and Nurr1-null heterozygous
(+/−) mice to determine the mechanism(s) regulating Nur77
and Nurr1 expression. Laser capture microdissection and real-
time PCR was used to measure Nurr1 and Nur77 mRNA
levels in the ventral tegmental area (VTA). Nur77 expression
was significantly elevated 1 h after both GBL (twofold) and
eticlopride (fourfold). In contrast, GBL significantly de-
creased Nurr1 expression in both genotypes, while eticlopride
significantly increased Nurr1 expression only in the +/+ mice.
In a separate group of mice, haloperidol injection significantly
elevated Nur77 and Nor1, but not Nurr1 mRNA in the VTA
within 1 h and significantly increased tyrosine hydroxylase
(TH) and dopamine transporter (DAT) mRNA expression by
4 h. These data demonstrate that the NR4A genes are
dynamically regulated in dopamine neurons with maintenance
of Nurr1 expression requiring dopamine neuron activity while
both attenuation of dopamine autoreceptors activation and
dopamine neuronal activity combining to induce Nur77
expression. Additionally, these data suggest that induction of
NR4A genes could regulate TH and DAT expression and
ultimately regulate dopamine neurotransmission.
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Introduction
The NR4A genes consist of a group of transcription factors
that includes Nur77 (NR4A1), Nurr1 (NR4A2), and Nor1
(NR4A3). The NR4A proteins share a very similar DNA-
binding domain and DNA response element binding
properties. All three of these proteins can bind as mono-
mers to the octomeric sequence termed the Nur77 binding
response element (NBRE) or as hetero or homodimers on
the Nur77 response element, an inverted repeat of the
NBRE separated by six nucleotides, and induce reporter
gene expression in vitro (Wilson et al. 1991; Paulsen et al.
1995; Murphy et al. 1996; Philips et al. 1997; Maira et al.
1999; Maira et al. 2003). Although differences in DNA-
binding affinities and heterodimerization properties have
been reported, the similarities in DNA-binding properties
suggest that these proteins, when expressed together, could
have similar effects on target gene regulation. Additionally,
the NR4A transcription factors can serve as heterodimer
pairs with other transcription factors such as the retinoid X
receptor and COUP-TF (Perlmann and Jansson 1995; Wu et
al. 1997). The NR4A genes are also inducible transcription
factors which have been shown to be induced rapidly in
neurons, thus providing a mechanism of coupling changes
in electrophysiology and/or neurotransmission with regula-
tion of neuron gene expression (Hosford et al. 1995; Xing
et al. 1997; Honkaniemi and Sharp 1999).
The mesolimbic dopamine neurons, which are located in
the ventral tegmental area (VTA) and innervate the nucleus
accumbens as well as limbic and cortical structures, have
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been implicated in a number of brain functions including
regulating reward and discerning relevant stimuli (reviewed
in Tzschentke 2001). Aberrant function of this pathway has
been implicated in symptoms of schizophrenia, attention
deficit-hyperactivity disorder, and addiction. The NR4A
transcription factors have been shown to have important
roles in regulating dopamine neurotransmission. Nurr1 is
expressed in mesencephalic dopamine neurons during
development and is necessary for differentiation of these
neurons (Zetterström et al. 1997; Castillo et al. 1998;
Saucedo-Cardenas et al. 1998). Additionally, Nurr1 is
necessary for survival of these neurons and has been
implicated in regulation of genes necessary for dopamine
neurotransmission such as tyrosine hydroxylase (TH), GTP
cyclohydrolase, dopamine transporter (DAT), and vesicular
monoamine transporter (Iwawaki et al. 2000; Sacchetti et
al. 2001; Hermanson et al. 2003; Jankovic et al. 2005; Eells
et al. 2006; Gil et al. 2007; Kadkhodaei et al. 2009). Nurr1
function is particularly important for mesoaccumbens
dopamine neurotransmission as reduced Nurr1 expression,
as found in Nurr1-null heterozygous mice, results in
reduced dopamine levels and reduced dopamine synthesis
in the nucleus accumbens (Eells et al. 2002; Eells et al.
2006). In contrast to Nurr1, Nur77 and Nor1 are typically
expressed in targets of dopamine innervations such as the
medium spiny neurons in the striatum and nucleus
accumbens and can affect dopamine neurotransmission
(Zetterström et al. 1996; Maheux et al. 2005; Gilbert et al.
2006). Although Nur77 and Nor1 expression is low,
(undetectable with in situ hybridization) in mesencephalic
dopamine neurons, expression of these genes can be
induced by antipsychotic drugs which primarily are
antagonist of the dopamine D2 receptor (Saucedo-Cardenas
and Conneely 1996; Maheux et al. 2005). Due to the
similar DNA-binding properties between the NR4A pro-
teins and the function of Nurr1 in mesoaccumbens
dopamine neurons, expression of Nur77 and Nor1 in
dopamine neurons could have important implications on
dopamine neurotransmission.
Currently, the mechanism(s) responsible for regulating
expression of the NR4A genes and the consequence(s) on
dopamine neuron gene expression after induction of NR4A
genes has not been investigated. The first part of the current
study was designed to determine the mechanism(s) respon-
sible for regulation of Nur77 and Nurr1 expression. The
current experiments used the drug γ-butyrolactone (GBL),
which blocks impulse flow of dopamine neurons, reducing
dopamine release, and subsequent activation of the dopa-
mine autoreceptor, to differentiate between dopamine
neuron activity and release from activation of the dopamine
autoreceptor. A systemic D2 receptor antagonist, however,
will similarly reduce activation of the dopamine autorecep-
tor but also results in an increase in activity of the
dopamine neurons with an increase in dopamine release
(reviewed in Tzschentke 2001). Expression of Nur77 and
Nurr1 mRNA was compared after treatment with the D2
receptor antagonist eticlopride and GBL. The second part of
the study was designed to determine the effect of induction
of NR4A genes by a dopamine D2 receptor antagonist
(haloperidol) on dopamine neurotransmission gene expres-
sion. Nur77 and Nurr1 expression was elevated by
eticlopride, while GBL significantly reduced Nurr1 expres-
sion but elevated Nur77 expression. Furthermore, antago-
nism of the D2 receptor, which significantly increased
Nur77 and Nor1 expression at 1 h, resulted in a significant
increase in TH and DAT expression at 4 h. These data
suggest that both Nur77 and Nurr1 are dynamically
regulated in the VTA and that these changes may have
direct consequences on dopamine neurotransmission genes.
Methods
Chemicals and Reagents
Haloperidol, GBL, and eticlopride were purchased from
Sigma with 99% purity. Acetic acid, 0.1 M, was used to
dissolve haloperidol into solution, which was then further
diluted with saline to reach a final concentration 0.1 mg/ml.
Animals
Animals were housed at Mississippi State University in an
AAALAC-accredited facility on 12-h light/dark cycle with
food and water available ad libitum. Nurr1-null heterozy-
gous mice used for the first part of this study were obtained
from a colony bred at Mississippi State University
originally produced in the laboratory of Dr. Vera Nikodem
at the National Institute for Diabetes and Digestive and
Kidney Diseases (Castillo et al. 1998). Mice were geno-
typed as previously described to distinguish +/− and +/+
mice (Castillo et al. 1998). At 19–21 days of age, mice
were weaned and housed in groups of three to five per cage.
Ninety-day-old male HSD:ICR outbred mice were pur-
chased from Harlan Bioproducts for Science for the second
part of this study. All mice were housed in cages with steel
grid lids and all cages were located in the same room. All
procedures were performed in accordance with the National
Institutes of Health Guide for the Care and Use of
Laboratory Animals, and study protocols were approved
by the Institutional Animal Care and Use Committee at
Mississippi State University. All animals used in this
project were housed in the AAALAC-accredited facilities
of the College of Veterinary Medicine, Mississippi State
University. The individual room temperatures were main-
tained between 18°C and 22°C with food and water ad
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libitum. Care of the mice was overseen by a laboratory
animal veterinarian.
For the first experiment, adult Nurr1-heterozygous and
wild-type littermate mice were divided into four groups of
six mice in each genotype (+/+ and +/−) and treatment
(vehicle, GBL, and eticlopride). Each mouse received a
single intraperitoneal injection of 0.9% saline, 1 mg/kg
eticlopride, or 750 mg/kg GBL. For the second experiment,
a total of 32 HSD:ICR outbred mice were divided into two
groups consisting of vehicle or haloperidol treatment with
16 mice in each group. Haloperidol was administered via
intraperitoneal injection at a dose of 1 mg/kg. Saline acetic
acid solution served as our vehicle treatment. Mice were
then sacrificed 1 and 4 h after either vehicle or haloperidol
injection, with eight mice in each treatment and time point.
At the end of the experiments, mice were euthanized by
CO2 asphyxiation. After asphyxiation, all mice were
decapitated and the brain removed. A coronal cut was
made in the brain at approximately 1 mm caudal to bregma,
which separated the brain into two distinct regions
(midbrain and forebrain). The brain tissue was frozen on
dry ice and stored at −80°C.
Tissue Dissection for RNA Isolation
The brainstem of the HSD:ICR outbred mice were attached
to a custom-made cold aluminum tissue slicer using Tissue-
Tek O.C.T. compound and sectioned into 400–600-μm
frozen sections with a razor blade. Using an 18-gauge blunt
needle, punches from the VTA were made for RNA
isolation. To isolate the VTA in the Nurr1 mice,
immunohistochemistry-guided, laser capture microdissec-
tion was used. In the Nurr1 transgenic mice, the brainstem
was sectioned into 10-μm section with a cryostat and
alternate sections were collected onto silanized slides. For
each mouse, one slide was processed for fluorescent
tyrosine hydroxylase immunohistochemistry as previous
described (Eells et al. 2001). Briefly the section was fixed
with 4% paraformaldehyde for 30 min, washed in
phosphate-buffered saline, incubated with tyrosine hydrox-
ylase primary antibody (Chemicon) at a concentration of
1:2,000 for 2 h, rinsed with phosphate-buffered saline then
incubated in goat anti-rabbit IgG conjugated to AlexaFluor
488 (Invitrogen) for 2 h. Sections were counter-stained with
DAPI and coverslipped with Permount. For laser capture
microdissection, another slide with adjacent sections from
the immunostained slide, was fixed for 2 min in acetone at
4°C, air-dried, then dehydrated through a series of concen-
trations of RNase-free ethanol (75–80–95–100–100%) then
cleared with two successive incubations in xylene. Using
the slide labeled for tyrosine hydroxylase immunohisto-
chemistry as a guide (Fig. 1), the region of the sections with
tyrosine hydroxylase immunoreactive neurons in the VTA
was outlined and captured onto CapSure Macro LCM caps
(Applied Biosystems).
Tissue Dissection for Catecholamine Measurements
The frozen forebrain tissue was mounted in a custom-made
tissue slicer with O.C.T. compound (Sakura Finetek, Torrance,
CA) and 600–800-μm frozen sections were cut and mounted
on glass slides. Micropunches of the dorsal striatum were
isolated using a blunt 20-gauge needle while micropunches of
the nucleus accumbens were isolated with an 18-gauge blunt
needle. Micropunches were used for determination of dopa-
mine and metabolite levels using high-performance liquid
chromatography and electrochemical detection.
Catecholamine Measurements
Tissue catecholamine levels were measured as previously
described (Eells and Brown 2009). Tissues micropunches
were homogenized in 100 μl of 0.1 M perchloric acid,
cleared by two rounds of centrifugation at 10,000×g and the
supernatant was injected into a high-pressure liquid
chromatography system consisting of a Waters 2695
Separation module, a SupleCosil LC-18-DB column with
the Waters 2465 electrochemical detector. The electrochem-
ical detector was set at 5 nA and an Ec=+0.67 V using a
mobile phase of 100 mM phosphate, 17.5% methanol,
25 mM EDTA, and 1 mM octyl sodium sulfate at pH 3.65.
Fig. 1 Dopamine neurons in the ventral tegmental area are shown
after tyrosine hydroxylase immunohistochemistry (a). This area was
used to determine the distribution of dopamine neurons and used to
dissect tissue from an adjacent section processed for laser capture
microdissection (b)
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These conditions provide good separation and detection of
dopamine and its metabolite 3,4 dihydroxyphenylacetic
acid (DOPAC). The quantity of each compound was
determined based on the response of a known amount of
standards. The BCA protein assay was performed on the
remaining pellets to normalize based on amount of protein
in each micropunch. Pellets were solubilized with 100 μl of
0.5 M NaOH by incubating at 37°C for 1 h. Distilled water
was then added to the samples (200 μl to nucleus
accumbens samples) and incubated for an additional
30 min. The samples were loaded into a 96-well plate and
assayed using the ThermoMax microplate reader with
Softmax pro software. Bovine serum albumin was used as
the protein standard.
RNA Isolation and Q-PCR
RNA from micropunches of the VTA was isolated using
Absolutely RNA Microprep Kit according to manufac-
turer's directions (Stratagene). After isolation of RNA,
cDNA was made using the Qiagen omniscript reverse
transcriptase kit using oligo dT and random hexamers.
RNA from the VTA dissected using laser capture micro-
dissection was isolated using the PicoPure RNA isolation
kits (Molecular Devices). RNA was reverse transcribed
using Superscript III with a combination of oligo dT and
random hexamers according to manufactures instructions
(Invitrogen). Lux primers were designed to measure Nur77,
Nurr1, Nor1, TH, DOPA decarboxylase, DAT, dopamine
D2 receptor, vesicular monoamine transporter 2, and the
internal control gene β-actin (Table 1). To determine gene
expression using quantitative PCR, Platinum qPCR
Supermix-UDG was used on the Strategene Mx3005p
QPCR system. All gene expression data was determined
based on standard curves for each gene using whole brain
RNA and normalized to β-actin. The average ratio of the
target gene and β-actin for the vehicle treatment was
normalized to 100% and differences from the vehicle were
calculated for each treatment.
Statistical Methods
Student'st test was used for comparisons of neurochemical
data and quantitative PCR data between the haloperidol and
vehicle treatments. ANOVA with Fisher's PLSD post hoc
tests were used to make comparisons across drug treatments
and genotype for neurochemical data and quantitative PCR
data. A p value of less than 0.05 was used as the level of
significance.
Results
Mechanisms Regulating NR4A Gene Expression
To investigate the regulation of the NR4A genes, Nurr1-
null heterozygous and wild-type mice were used. Based on
the neurochemistry results, GBL produced a modest but not
significant increase in tissue dopamine in the nucleus
accumbens. Eticlopride, however, produced a modest
reduction in tissue dopamine levels (Table 2). GBL
treatment produced a significant twofold increase in
Nur77 expression in the VTA, while eticlopride treatment
had a more striking effect, producing a fourfold increase in
Nur77 expression in the VTA. Each of these effects was
similar across Nurr1 genotypes (Fig. 2). These data
demonstrate that directionally, GBL and eticlopride had
similar effects on Nur77 expression with eticlopride having
a greater effect on inducing Nur77 expression. Nurr1
expression, however, was regulated differently as compared
to Nur77. Measurement of Nurr1 expression in the VTA
revealed a significant reduction in Nurr1 expression in both
the +/+ and +/− mice (Fig. 3). In fact, a greater reduction in
Nurr1 was found in the heterozygous mice even though
dopamine levels were less affected in these mice. One
technical note is that these Lux primers for Nurr1 measure
Nurr1 between exons 7 and 8. Even though the Nurr1 gene
is disrupted with a neomycin sequence in exon 3, it is still
fully transcribed through exons 7 and 8. Interestingly, Nurr1
Table 1 Lux primers used for quantitative real-time PCR
Gene Forward primer Reverse primer
β-actin GGATCAGCAAGCAGGAGTACGA CGGACAACGCAGCTCAGTAACAGTCG
Nur77 (NR4A1) CGGGCTTGGGTGTTGATGTTCCG TGTCGATCAGTGATGAGGACCA
Nurr1 (NR4A2) ATTGCTGCCCTGGCTATGGT GACCATCCCATTATTGAAAGTCACATGGTC
Nor1 (NR4A3) CGCACGGATGGTTAAGGAAGTTGTGCG GGCTCCTCTTGTAGTGGGCTCT
Dopamine transporter CACATACCCCTGCTTCCTCCTGTATGTG AGGATGTGGCGATGATCCAG
Tyrosine hydroxylase GACATTGCCCAGAGATGCAAGTCCAATGTC TGTTGGCTGACCGCACATTT
DOPA decarboxylase CACCTTCCAGTAGGGCCACCAAGGTG GGGAGGAGTGATCCAGGGAAGT
Dopamine D2 receptor CACCTAAGTGAACAGGCGGAGAATGGATG AGGATGTGGCGATGATCCAG
Vesicular monoamine transporter CACCAGAGACAGCTCCTTTCCTGGTG GGATGGCTGGAGCACAAAGAG
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expression was differentially affected between the +/+ and +/−
mice as a result of eticlopride treatment. Eticlopride signifi-
cantly increased Nurr1 expression in +/+ mice but had no
effect on Nurr1 expression in the +/−mice (Fig. 3). However,
eticlopride had a greater effect on tissue dopamine levels in
the +/− than the +/+ mice (Table 2).
Dopamine Neurotransmission Gene Expression
After Induction of NR4A Genes
Male HSD:ICR outbred mice were used to investigate the
relationship between induction of NR4A genes and the
expression of dopamine neurotransmission genes in the
VTA in combination with effects on dopamine neurochem-
istry in the nucleus accumbens. Based on neurochemical
measurements, haloperidol treatment was effective at
altering dopamine neurotransmission. Haloperidol resulted
in a significant reduction in tissue dopamine levels at 1 h
but produced a significant increase in tissue dopamine
levels at 4 h (Table 3). The 1-h time point was chosen as
sufficient time to induce gene expression with a D2
receptor antagonist (Maheux et al. 2005). The 4-h time
point was chosen as sufficient time to determine how
changes in transcription factor expression could affect the
regulation of dopamine neurotransmission gene expression.
Measurement of gene expression revealed that 1 h after
haloperidol, Nur77 and Nor1 expression was significantly
elevated. Haloperidol, however, had no effect on Nurr1
expression (Fig. 4). Dopamine neurotransmission genes
were then measured in the VTA 4 h after haloperidol
treatment. This analysis revealed a significant increase in
TH and DAT mRNA expression. No significant changes in
DOPA decarboxylase, dopamine D2 receptor, or vesicular
monoamine transporter 2 were found (Fig. 5). Since both
TH and DAT have been implicated as being regulated by
Nurr1, these data suggest increased expression of other
Fig. 2 Nur77 expression in the ventral tegmental area after either
γ-butyrolactone or eticlopride in Nurr1 wild-type (+/+) and heterozy-
gous (+/−) mice. Both γ-butyrolactone and eticlopride significantly
increased Nur77 expression, with the exception of γ-butyrolactone in
the +/− mice. *p<0.05, significant difference from the vehicle treatment
after ANOVA with post hoc comparison
Table 2 Dopamine and DOPAC levels in +/+ and +/− mice treated
with GBL or eticlopride
Treatment Dopamine DOPAC
+/+ Vehicle 0.520±0.073 0.122±0.003
+/− Vehicle 0.566±0.074 0.145±0.023
+/+ γ-Butyrolactone 0.688±0.150 0.106±0.005
+/− γ-Butyrolactone 0.626±0.102 0.133±0.009
+/+ Eticlopride 0.449±0.066 0.114±0.003
+/− Eticlopride 0.370±0.046 0.114±0.007
All values in picograms per micrograms of protein
Fig. 3 Nurr1 expression in the ventral tegmental area after either
γ-butyrolactone or eticlopride in Nurr1 wild-type (+/+) and
heterozygous (+/−) mice. While γ-butyrolactone significantly decreased
Nurr1 expression in both +/+ and +/− genotypes, eticlopride signifi-
cantly increased Nurr1 expression only in the +/+ mice with no effect in
the +/− mice. *p<0.05, significant difference from the vehicle treatment
after ANOVA with post hoc comparison
Table 3 Dopamine and DOPAC levels after haloperidol treatment
Treatment Dopamine DOPAC
Vehicle, 1 h 0.478±0.0785 0.0941±0.0041
Haloperidol, 1 h 0.109±0.0205* 0.0922±0.0177
Vehicle, 4 h 0.5885±0.203 0.1422±0.025
Haloperidol, 4 h 1.434±0.284* 0.3208±0.0342*
All values in picograms per microgram of protein
*p<0.05 after ANOVA and post hoc comparison
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NR4A genes (i.e., Nur77 and Nor1) could have an
important role in regulation of dopamine neurotransmission
genes that result from treatment with a D2 receptor
antagonist.
Discussion
The current study investigated the regulation of NR4A gene
expression in the VTA as well as subsequent effects on
dopamine neurotransmission gene expression. The first
aspect of these studies was to determine the mechanisms
that regulate NR4A gene expression. Previous experiments
have suggested that antagonism of the D2 receptor is the
mechanism through which Nurr1 expression is enhanced in
dopamine neurons while stimulation of the D2 receptor can
reduce Nurr1 expression. Evidence in support of antago-
nism of the D2 receptor increasing Nurr1 is first that Nurr1
levels are elevated in D2 receptor knockout mice and
second, Nurr1 levels are increased after systemic treatment
with D2 receptor antagonists (Tseng et al. 2000; Maheux et
al. 2005). Furthermore, Bannon et al. reported reduced
Nurr1 expression with cocaine use, a condition that
decreases dopamine reuptake which could result in exces-
sive autoreceptor stimulation (Bannon et al. 2002). By
comparing GBL, which blocks impulse flow of dopamine
neurons and subsequent dopamine release, with a systemic
D2 receptor antagonist, which results in an increase in
activity of dopamine neurons and an increase in dopamine
release with reduced activation of the dopamine autorecep-
tor (reviewed in Tzschentke 2001), the effects of dopamine
neuron activity could be differentiated from activation of
the dopamine autoreceptor. The current data found that
GBL significantly and rapidly (within 1 h) reduced Nurr1
expression in the VTA. The D2 receptor antagonist
eticlopride had only a modest effect on Nurr1 expression.
This treatment, however, was sufficient to significantly
induce Nur77 expression.
These data demonstrate several important observations
about the regulation of Nurr1 and Nur77 expression. First,
Nurr1 expression is regulated differently than that of
Nur77. Specifically, impulse flow in the VTA dopamine
neurons appears to be essential for maintaining Nurr1
expression with the capacity for a rapid downregulation in
Nurr1 RNA levels with reduced dopamine neuron activity.
This is demonstrated by the reduction in Nurr1 expression
within 1 h after GBL treatment. The electrophysiology
properties of VTA dopamine neurons mainly consist of
spontaneously active neurons that change to burst firing in
response to relevant environmental stimuli such as reward
Fig. 4 Dopamine neuron gene expression in the ventral tegmental
area 1 h after a 1-mg/kg systemic injection of haloperidol. Nur77 and
Nor1 were significantly elevated after treatment, while no changes in
Nurr1 expression were found. *p<0.05, significant difference from the
vehicle treated after Student's t test
Fig. 5 Dopamine neuron
gene expression in the ventral
tegmental area 4 h after







D2 receptor, and vesicular
monoamine transporter 2
were not significantly affected.
*p<0.05, significant difference
from the vehicle treated after
Student's t test
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(Tzschentke 2001). Based on the current data, we propose
that spontaneous and/or burst activity of VTA dopamine
neurons is necessary for maintaining Nurr1 expression.
Also demonstrated by using the Nurr1 +/+ and +/− mice
and eticlopride is that dopamine neuron function resulting
from a deficit in Nurr1 has an impact on whether a D2
receptor antagonist can induce Nurr1 expression. These
data suggest that a D2 receptor antagonist is not necessarily
sufficient to increase Nurr1 expression and that the level of
Nurr1 function can impact the responsiveness of these
neurons to D2 receptor antagonists. The Nurr1 +/−
genotype has been shown to increase basal extracellular
dopamine levels in the shell of the nucleus accumbens
(Moore et al. 2008). This change could alter the respon-
siveness of both post-synaptic dopamine receptors and the
dopamine autoreceptors and change the way the +/− VTA
dopamine neurons respond to a D2 receptor antagonist.
In dopamine neurons in the VTA, Nurr1 is expressed at
relatively high levels. Basal Nur77 expression, however, is
low, allowing for a large capacity for a rapid, relative increase
in expression. Previous data has implicated increases in
neuronal activity, such as after a seizure, as a mediator to
induce Nur77 expression (Watson andMilbrandt 1989, 1990).
In VTA dopamine neurons, the expression of Nur77 appears
to be regulated by a combination of impulse flow as well as
reduced activation of the dopamine autoreceptors. GBL
treatment caused a modest twofold increase in Nur77
expression while eticlopride caused a fourfold increased
Nur77 expression. Based on this data, we propose that the
combination of reduced activation of the D2 autoreceptor
that results from GBL treatment and an increase in dopamine
neuron firing rate and dopamine release that results from
eticlopride treatment combine to contribute to the increase in
Nur77 expression.
The second experiment was conducted to determine if
induction of Nur77 and/or Nor1 could have functional
consequences on the regulation of dopamine neurotransmis-
sion genes. Both Nur77 and Nor1 were induced after 1 h of
treatment with haloperidol while Nurr1 was not. To determine
if this could have effects on dopamine neurotransmission,
samples were taken 4 h after haloperidol treatment and
dopamine neurotransmission gene expression was measured
in the VTA. Our results found an increase in TH and DAT
expression at 4 h after haloperidol treatment. As the NR4A
transcription factors all possess similar abilities to bind to
response elements in promoter regions of target genes, any
increases in Nur77 or Nor1 levels could function similarly to
Nurr1 and therefore, affect the expression of the same genes
that are controlled by Nurr1 and regulate dopamine neuro-
transmission genes and dopamine neurotransmission.
Previous research has demonstrated that TH gene
expression can be directly regulated by Nurr1 (Sakurada
et al. 1999; Cazorla et al. 2000). The TH promoter region
contains known sequences of NBRE that are necessary for
Nurr1 regulation of reporter gene expression (Kim et al.
2003). Additionally, Nurr1 can induce TH gene expression
in embryonic stem cells. The role of Nurr1 in the regulation
of the DAT is not as straightforward. No difference in DAT
expression was found in the VTA of the Nurr1 +/− mice
(Eells et al. 2006). However, Bannon et al. suggested a role
for Nurr1 in DAT regulation as cocaine users who have
Nurr1 deficiencies due to chronic use of the drug also had
reduced DAT expression (Bannon et al. 2002). The
transcriptional activity of human DAT has been shown to
be enhanced by Nurr1 (Sacchetti et al. 1999; Sacchetti et al.
2001). Nurr1 regulation of the DAT promoter was found to
be independent of the NBRE and the mechanism through
which Nurr1 could regulate transcription from this promot-
er is currently unclear (Sacchetti et al. 2001). This research
also demonstrated that both Nurr1 and Nur77 could
increase reporter gene expression from the DAT promoter
in SN4741 dopamine cell lines, although Nurr1 effects were
greater than that of Nur77 (Sacchetti et al. 2001). Nor1,
however, had no significant effect on the DAT promoter in
this study (Sacchetti et al. 2001). Although the expression
of Nur77 and Nor1 relative to TH and DAT are only
correlative, these data still provide evidence that induction
of Nur77 and Nor1 could be involved in the regulation of
dopamine neurotransmission genes and could have a role in
how dopamine neurons are affected by antipsychotics.
Further data is needed to directly confirm the role of
induction of Nur77 and/or Nor1 in the regulation of these
dopamine neurotransmission genes, such as in knockout
mice or using RNA interference to block expression. Also
of interest is whether the NR4A genes are regulated in
dopamine neurons under physiological conditions and not
just the result of pharmacological manipulation.
The dopamine D2 receptor, which serves as the primary
autoreceptor, is negatively coupled to cAMP levels and
protein kinase A. Blocking the D2 receptor increases
dopamine synthesis via phosphorylation of TH. Changes
in dopamine release can, therefore, alter phosphorylation of
TH and alter dopamine synthesis. Based on the observa-
tions that Nurr1 is implicating in regulating TH, that
dopamine synthesis is impaired in Nurr1 +/− mice, and
that Nur77, Nurr1, and Nor1 mRNA expression is
dynamically regulated, we propose that NR4A levels
function as a longer feedback loop between dopamine
neuron activity and subsequent regulation of gene expres-
sion. Based on this hypothesis, reduced activity of
dopamine neuron which results in reduced Nurr1 expres-
sion, will produce a reduction in dopamine neurotransmis-
sion genes such as TH. Additionally, increased neuron
activity could enhance Nurr1, or the functionally similar
genes Nur77 and/or Nor1 to increase expression of TH. Just
as there is considerable feedback from the dopamine
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autoreceptor to regulate dopamine synthesis, release, and
reuptake, this hypothesizes a similar feedback mechanism
that is mediated by altering gene and protein expression as
compared to the relatively rapid autoreceptor feedback
mediated primarily via phosphorylation.
Conclusions
These data suggest that the maintenance of Nurr1 expression
requires impulse flow in VTA dopamine neurons while the
combination of reduced D2 receptor activation coupled with
dopamine neuron activity and/or dopamine release, appears to
be the mechanism for increasing Nur77 expression. Since the
NR4A genes have been linked with the regulation of
dopamine neurotransmission, the current data demonstrate
that elevation of Nur77 and Nor1 expression in the VTA
correspond to subsequent elevation of the dopamine neuro-
transmission genes TH and the DAT. This suggests that
induction of Nur77 and/or Nor1 could also have important
implications in the regulation of dopamine neurotransmission.
Therefore, the regulation of NR4A genes could be a very
important mechanism in regulating dopamine neurotransmis-
sion and expression of dopamine neurotransmission genes.
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